Projects of the Foundation
Differentiation of early prostate cancer that may be latent (indolent) from one that is aggressive and clinically important and should be treated.
Development of response criteria (biological markers), other than prostate-specific antigen, to evaluate the effectiveness of new therapeutic regimens and/or agents.
Refinement of the "immunostaging" of patients as a means to:
-Assess and correlate their immunologic and clinical status prior to and following therapy and,
-Assess their potential to respond to immunologic-based therapy